---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-002475"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:29:58.130164+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Black Diamond submits IND for BDTX-1535 ahead of schedule; cash runway extended to 2024

## Summary
- IND submitted for BDTX-1535 (CNS-penetrant EGFR inhibitor) for GBM and NSCLC; Phase 1 expected Q1 2022 subject to FDA allowance.
- Company to enroll additional patients in BDTX-189 safety expansion; Phase 2 start gated pending further data.
- Ended 2021 with ~$210M cash, sufficient to fund operations into 2024.
- Anticipates IND-enabling studies for CNS-penetrant BRAF program in 2022.
- Preclinical data shows BDTX-1535 activity in intracranial tumor models; targets ~50% of GBM patients.

## SEC filing metadata
- accession: 0001104659-22-002475
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000110465922002475/0001104659-22-002475-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000110465922002475/tm222372d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-002475
- JSON: https://secwatch.observer/filing/0001104659-22-002475.json
- Plain text: https://secwatch.observer/filing/0001104659-22-002475.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.